


Indomethacin

Cat. No.:	HY-14397
CAS No.:	53-86-1
Molecular Formula:	C ₁₉ H ₁₆ ClNO ₄
Molecular Weight:	357.79
Target:	COX; Antibiotic; Influenza Virus; Bacterial
Pathway:	Immunology/Inflammation; Anti-infection
Storage:	4°C, protect from light * In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (279.49 mM; Need ultrasonic)
Ethanol : 12.5 mg/mL (34.94 mM; Need ultrasonic)
H₂O : < 0.1 mg/mL (insoluble)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	2.7949 mL	13.9747 mL	27.9494 mL
	5 mM	0.5590 mL	2.7949 mL	5.5899 mL
	10 mM	0.2795 mL	1.3975 mL	2.7949 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.08 mg/mL (5.81 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (5.81 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (5.81 mM); Clear solution
- Add each solvent one by one: 10% EtOH >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 1.25 mg/mL (3.49 mM); Clear solution
- Add each solvent one by one: 10% EtOH >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 1.25 mg/mL (3.49 mM); Clear solution
- Add each solvent one by one: 10% EtOH >> 90% corn oil
Solubility: ≥ 1.25 mg/mL (3.49 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	Indomethacin (Indometacin) is a potent, orally active COX1/2 inhibitor with IC ₅₀ values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin has anticancer activity and anti-infective activity. Indomethacin can be used for cancer, inflammation and viral infection research ^{[1][2][3]} .																	
IC₅₀ & Target	Human COX-1 18 nM (IC ₅₀ , in CHO cells)	Human COX-2 26 nM (IC ₅₀ , in CHO cells)																
In Vitro	<p>Indomethacin (Indometacin) (0-150 μM; 24 hours; 3LL-D122 cells) has anticancer activity in vitro^[2].</p> <p>Indomethacin (Indometacin) (0-1000 μM) protects the host cells from damage caused by the virus through activates PKR, resulting in eIF2α phosphorylation, and in turn shutting of translation of viral protein and inhibiting replication of the virus (IC₅₀=2μM)^[3].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[2]</p> <table border="1" data-bbox="365 594 1515 825"> <tr> <td>Cell Line:</td> <td>3LL-D122 cells (highly metastatic variant of mouse LLCarcinoma cells)</td> </tr> <tr> <td>Concentration:</td> <td>0, 20, 50, 100 and 150μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 hours</td> </tr> <tr> <td>Result:</td> <td>Inhibited cell viability at 20 mM, with 50% inhibition at 60 mM.</td> </tr> </table> <p>Cell Viability Assay^[2]</p> <table border="1" data-bbox="365 898 1515 1161"> <tr> <td>Cell Line:</td> <td>3LL-D122 cells (highly metastatic variant of mouse LLCarcinoma cells)</td> </tr> <tr> <td>Concentration:</td> <td>0, 30 and 80μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 hours</td> </tr> <tr> <td>Result:</td> <td>Decreased in the percentage of cells at the G2/M phase and increased in the percentage of cells at G1 phase.</td> </tr> </table>		Cell Line:	3LL-D122 cells (highly metastatic variant of mouse LLCarcinoma cells)	Concentration:	0, 20, 50, 100 and 150μM	Incubation Time:	24 hours	Result:	Inhibited cell viability at 20 mM, with 50% inhibition at 60 mM.	Cell Line:	3LL-D122 cells (highly metastatic variant of mouse LLCarcinoma cells)	Concentration:	0, 30 and 80μM	Incubation Time:	24 hours	Result:	Decreased in the percentage of cells at the G2/M phase and increased in the percentage of cells at G1 phase.
Cell Line:	3LL-D122 cells (highly metastatic variant of mouse LLCarcinoma cells)																	
Concentration:	0, 20, 50, 100 and 150μM																	
Incubation Time:	24 hours																	
Result:	Inhibited cell viability at 20 mM, with 50% inhibition at 60 mM.																	
Cell Line:	3LL-D122 cells (highly metastatic variant of mouse LLCarcinoma cells)																	
Concentration:	0, 30 and 80μM																	
Incubation Time:	24 hours																	
Result:	Decreased in the percentage of cells at the G2/M phase and increased in the percentage of cells at G1 phase.																	
In Vivo	<p>Indomethacin can be used to induce gastric ulcer models. After oral administration, the drug is absorbed rapidly and completely, although there are interindividual and intraindividual variations. Typically, the plasma peak concentration (2-3 μg/mL) is reached within 1-2 hours. However, coadministration with food reduces and delays the peak concentration without affecting the total absorption. At therapeutic concentrations, 90% of Indomethacin is bound to albumin in the plasma^[4].</p> <p>Induction of gastric ulceration^{[5][6]}</p> <ul style="list-style-type: none"> ● Background <p>Indomethacin can cause gastric ulceration by various mechanisms, including injury through inhibition of prostaglandin (PG) synthesis, reduction in local blood flow, regional irritation, and inhibition of tissue regeneration.</p> ● Specific Modeling Methods <div style="border: 1px solid black; padding: 10px; margin-top: 10px;"> <p>Rat: albino Sprague-Dawley • male • adult (period: 2 weeks)</p> <p>Administration: 100 mg/kg • p.o. • single dose</p> </div> 																	

Note

- (1) All animals fasted 24 h before drug administration.
- (2) Indomethacin were dissolved in saline with 5% NaOH.

Modeling Indicators

Gastric tissue macroscopic alterations: Showed prominent mucosal folds and severe erosion, pronounced ulceration and bleeding foci in the gastric mucosa.

Histopathological changes: Showed severe erosion of the mucosa, reaching down to the lamina muscularis; observed hemorrhagic infiltration, edema in the submucosa, and severe hyperemia of the vessels.

Molecular changes: Showed intense Tnf- α expression.

Biochemical changes: Increased MDA, TOS levels, reduced TAS levels, CAT and GPx activities and GSH levels.

- Correlated Product(s): Indomethacin sodium hydrate (HY-14397A)
- Opposite Product(s): Carnosic acid (HY-N0644)

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats ^[1]
Dosage:	0.01-10 mg/kg
Administration:	Oral administration; for 3 hours
Result:	Inhibited the carrageenan-induced rat paw oedema (ED ₅₀ =2.0 mg/kg) and hyperalgesia (ED ₅₀ =1.5 mg/kg) in a dose-dependent manner.

Animal Model:	Male C57BL/6J mice ^[2]
Dosage:	10 mg/mL
Administration:	Oral administration; daily, for 29 days
Result:	Delayed the onset of tumor growth and the initial growth rate of the footpad tumors.

CUSTOMER VALIDATION

- J Extracell Vesicles. 2024 Dec;13(12):e70025.
- J Extracell Vesicles. 2024 Apr;13(4):e12426.
- Adv Sci (Weinh). 2024 Dec 5:e2410360.
- Biomaterials. 16 September 2022.
- Hepatology. 2023 Feb 1;77(2):456-465.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Riendeau D, et, al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. *Br J Pharmacol*. 1997 May;121(1):105-17.
- [2]. Eli Y, et, al. Comparative effects of indomethacin on cell proliferation and cell cycle progression in tumor cells grown in vitro and in vivo. *Biochem Pharmacol*. 2001 Mar 1;61(5):565-71.
- [3]. Amici C, et, al. Inhibition of viral protein translation by indomethacin in vesicular stomatitis virus infection: role of eIF2 α kinase PKR. *Cell Microbiol*. 2015 Sep;17(9):1391-404.
- [4]. Helleberg L, et, al. Clinical Pharmacokinetics of indomethacin. *Clin Pharmacokinet*. 1981 Jul-Aug;6(4):245-58.
- [5]. Sabiu S, et, al. Indomethacin-induced gastric ulceration in rats: Protective roles of Spondias mombin and Ficus exasperate. *Toxicol Rep*. 2015 Jan 8;2:261-267.
- [6]. Danisman B, et, al, Carnosic Acid Ameliorates Indomethacin-Induced Gastric Ulceration in Rats by Alleviating Oxidative Stress and Inflammation. *Biomedicines*. 2023 Mar 9;11(3):829.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA